Combination study with JS016 and LY-CoV555 for patients with mild-to-moderate covid-19 symptoms met primary and secondary endpoints

Data from new interim analysis of BLAZE-1 trial (n=267) showed that combination therapy with these two SARS-CoV-2 neutralising antibodies reduced viral load at day 11 (p=0.011), meeting the primary endpoint, as well as symptoms and COVID-related hospitalisation and A+E visits.

Source:

Biospace Inc.